Hydrafacial Results Presentation Deck
2022 outlook: demonstrated track record of execution
Strong track record of net sales outperformance
($mm)
$44.1 $47.5
29
Q1 21
+7.8%
$181
$66.5
$49.2
Net sales outlook
($mm)
$200
Q2 21
+35.2%
$235
■Consensus estimate ■Net sales
$68.1
$58.0
Q3 21
+17.5%
$71.1$77.9
Dec-20 May-21 Aug-21 Nov-21
2021 Outlook as of
Q4 21
+9.5%
$250 $260 $250
2021A
$68.1$75.4
Dec-20
Q1 22
+10.7%
$320-
$330
I
$103.5
$83.9
Q2 22
+23.4%
$330-
$340
$80.7$88.8
Q3 22
+10.0%
$340- $360-
$365
$350
Feb-22 May-22 Aug-22
2022 Outlook as of
I
I
I
I
Nov-22
Adjusted EBITDA¹ outlook
($mm)
$33
2021 Actual
+38% - +53%
YoY growth
$45 - $50
2022 Outlook
BEAUTYHEALTH™
Source: FactSet complied consensus; Note: figures may not foot due to rounding.
1. Non-GAAP measure. Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings with the SEC. The plan does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor
does it take into account the impact of our acquisitions, dispositions or financings during 2022. Our plan assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.View entire presentation